The Journal of antimicrobial chemotherapy · 2016
Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fransen Fiona, Melchers Maria J B, Meletiadis Joseph, Mouton Johan W
Аннотация
BACKGROUND: Although nitrofurantoin has been used for >60 years for the treatment of uncomplicated urinary tract infections, its pharmacodynamic properties are not fully explored. Use is increasing because of increasing resistance to other antimicrobials due to ESBLs.
METHODS: We tested nine ESBL+ and two ESBL- strains in time-kill assays. Bactericidal activity and regrowth were assessed for all species and concentrations. Early-phase pharmacodynamics was analysed with a sigmoidal Emax model and the maximal killing rate, slope and EC50/MIC ratio were determined for each species.
RESULTS: A bactericidal effect was found at ≥2× MIC for Enterobacter cloacae after 4-8 h, for Klebsiella pneumoniae after 8-10 h and for Escherichia coli after 12-16 h. Overall, no killing was observed at low sub-MIC concentrations, whereas regrowth was found at 0.5-1× MIC after a short decline in cfu. The lowest maximal killing rates were observed for E. coli (0.21 ± 0.05 h(-1)), followed by K. pneumoniae (0.37 ± 0.09 h(-1)) and E. cloacae (0.87 ± 0.01 h(-1)). Surprisingly, the Hill slopes for these three species were significantly different (10.45 ± 9.37, 2.68 ± 0.64 and 1.01 ± 0.06, respectively), indicating a strong concentration-dependent early-phase antibacterial activity against E. cloacae. EC50/MIC ratios were significantly lower for E. coli (0.24 ± 0.08 mg/L) and K. pneumoniae (0.27 ± 0.03 mg/L) as compared with E. cloacae (0.77 ± 0.18 mg/L).
CONCLUSIONS: Nitrofurantoin was bactericidal against all species, demonstrating an unusual differential pattern of activity with concentration-dependent-type killing behaviour against E. cloacae and time-dependent killing behaviour against E. coli, which may have significant consequences on species-dependent dosing regimens. The results also demonstrate that the pharmacodynamic properties of some drugs cannot be generalized within a family, here the Enterobacteriaceae.
METHODS: We tested nine ESBL+ and two ESBL- strains in time-kill assays. Bactericidal activity and regrowth were assessed for all species and concentrations. Early-phase pharmacodynamics was analysed with a sigmoidal Emax model and the maximal killing rate, slope and EC50/MIC ratio were determined for each species.
RESULTS: A bactericidal effect was found at ≥2× MIC for Enterobacter cloacae after 4-8 h, for Klebsiella pneumoniae after 8-10 h and for Escherichia coli after 12-16 h. Overall, no killing was observed at low sub-MIC concentrations, whereas regrowth was found at 0.5-1× MIC after a short decline in cfu. The lowest maximal killing rates were observed for E. coli (0.21 ± 0.05 h(-1)), followed by K. pneumoniae (0.37 ± 0.09 h(-1)) and E. cloacae (0.87 ± 0.01 h(-1)). Surprisingly, the Hill slopes for these three species were significantly different (10.45 ± 9.37, 2.68 ± 0.64 and 1.01 ± 0.06, respectively), indicating a strong concentration-dependent early-phase antibacterial activity against E. cloacae. EC50/MIC ratios were significantly lower for E. coli (0.24 ± 0.08 mg/L) and K. pneumoniae (0.27 ± 0.03 mg/L) as compared with E. cloacae (0.77 ± 0.18 mg/L).
CONCLUSIONS: Nitrofurantoin was bactericidal against all species, demonstrating an unusual differential pattern of activity with concentration-dependent-type killing behaviour against E. cloacae and time-dependent killing behaviour against E. coli, which may have significant consequences on species-dependent dosing regimens. The results also demonstrate that the pharmacodynamic properties of some drugs cannot be generalized within a family, here the Enterobacteriaceae.